№ files_lp_4_process_1_30989
File format: docx
Character count: 133001
File size: 213 KB
Official EMA product information source detailing therapeutic indications, composition, and administration guidelines for the monoclonal antibody bevacizumab marketed as Alymsys.
Year:
2026
Region:
European Union
Therapeutic Area:
Oncology / Cancer treatment
Document Type:
Product Information / Medicinal Product Monograph
Regulatory Agency:
European Medicines Agency (EMA)
Active Substance:
Bevacizumab
Pharmaceutical Form:
Concentrate for solution for infusion
Indications:
Metastatic colorectal cancer, metastatic breast cancer, nonsmall cell lung cancer, advanced renal cell cancer, epithelial ovarian/fallopian tube/primary peritoneal cancer, recurrent cervical cancer
Dosage and Administration:
Intravenous infusion, dose varies by indication
Target Audience:
Healthcare professionals
Link:
https://www.ema.europa.eu/en/medicines/human/epar/alymsys
Approval Status:
Approved
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
Pharmaceutical product information
Document type:
Approved product information
Organ / Institution:
European Medicines Agency (EMA)
Target audience:
Healthcare professionals
Contextual description:
Detailed product information for IMFINZI, including indications for various cancers and recommended dosages, aimed at healthcare providers involved in cancer treatment.
Year:
2026
Region / city:
International
Subject:
Oncology, Pharmacology
Document type:
Summary of Product Characteristics
Organization / institution:
Pharmaceutical manufacturer
Author:
Not specified
Target audience:
Healthcare professionals
Indications:
Adjuvant treatment of stage III colon cancer, treatment of metastatic colorectal cancer
Dosage form:
Concentrate for solution for infusion
Active substance:
Oxaliplatin
Excipients:
Polyethylene glycol 400
Administration route:
Intravenous infusion
Contraindications:
Hypersensitivity, breastfeeding, severe renal impairment, pre-existing myelosuppression, peripheral neuropathy
Special warnings:
Neurological toxicity, hypersensitivity reactions, peripheral neuropathy, RPLS
Method of preparation:
Dilution in 5% glucose solution before use
Population considerations:
Adults; not indicated for children; dose adjustment for renal impairment; no adaptation for elderly
Year:
2022
Region / city:
Geneva
Theme:
Appellations of Origin, Geographical Indications
Document type:
Proposal
Organization:
Lisbon Union Assembly
Author:
Secretariat
Target audience:
Delegations of Contracting Parties to the Lisbon Agreement
Period of validity:
From January 1, 2023
Approval date:
July 8, 2022
Amendment date:
N/A
Year:
2015
Region / City:
Tchaa, Bakam region
Subject:
Geographical indications, intangible cultural heritage, traditional silk weaving
Document type:
Case study
Organization / Institution:
WIPO, UNESCO
Author:
N/A
Target audience:
Academics, policymakers, cultural heritage professionals
Period of validity:
N/A
Approval date:
N/A
Modification date:
N/A
Context:
Case study on the practice of silk weaving and its cultural and legal protection in the Kan and Zan communities of Tchaa.
Version:
HNY v2.0
Replaces version:
HNY v1.0
Clinical content last reviewed:
November 2023
Next review date:
April 2028
Note:
RDTC v1.0 8th March 2024
Local review and adoption:
September 2025
Approved for use by HNY ICB:
1st October 2025
Clinical content reviewed and updated by RDTC:
November 2023
Year:
2016
Region / City:
N/A
Topic:
Radiology, Emergency Medicine
Document Type:
Guidelines
Organization / Institution:
Royal College of Radiologists
Author:
Susanne Soin, K Duncan, Catriona Reid, Akkib Rafique, Cheng Fang
Target Audience:
Medical Professionals, Emergency Department Clinicians, Radiologists
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Review:
25 July 2022
Document type:
Change Request
Specification:
3GPP TS 24.501
Change Request ID:
5501
Working group:
3GPP TSG-CT WG1
Meeting:
TSG-CT WG1 Meeting #143
Location:
Gothenburg
Meeting dates:
21–25 August 2023
Source organization:
Ericsson
Release:
Release 18
Work item code:
5G_eLCS_Ph3
Category:
Addition of feature
Affected domains:
Core Network, Mobile Equipment
Date:
14 August 2023
Current version:
18.3.1
Revision:
1
Clauses affected:
5.5.1.2.2; 5.5.1.2.4; 5.5.1.3.2; 5.5.1.3.4; 9.11.3.1; 9.11.3.5
Source type:
Technical standardization document
Year:
2023
Region / City:
Meriter Hospital
Topic:
Medical guidelines, MRI procedures
Document Type:
Guidelines
Organization:
Meriter Hospital
Author:
Venkata (Vinny) Meduri
Target Audience:
Medical staff, radiologists, ordering providers
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2018
Region / city:
Geneva
Theme:
Trademarks and Pharmaceutical Substances
Document Type:
Report
Organization:
World Intellectual Property Organization (WIPO)
Author:
WIPO Secretariat
Target audience:
National and regional industrial property offices, trademark examiners
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2022
Region / City:
European Union
Subject:
Geographical Indications (GIs), Domain Name Dispute Resolution
Document Type:
Public Comment
Institution:
European Commission
Author:
European Commission
Target Audience:
Stakeholders in IP rights, domain name systems
Action Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Version:
NENC v1.0
Date published:
12th December 2024
Changes since previous version:
Adapted from RDTC v1.2 published 26th November 2024
Planned review date:
March 2026
Licensed and agreed off-label indications:
Azathioprine, Mercaptopurine
Specialist:
NHS healthcare professionals
Target audience:
Healthcare professionals in adult services
Indication:
Auto-immune chronic active hepatitis, Behçet’s disease, inflammatory bowel disease, and others
Type of document:
Shared Care Protocol
Clinical guidelines:
BNF, NICE, BSR, BHPR
Local variations:
Gateshead
Period of use:
Ongoing, review by March 2026
Background:
Azathioprine and mercaptopurine as disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory conditions.
Note:
Date of approval
Year:
2020
Region / city:
United States
Topic:
Oncology, Consumer Advertising
Document type:
Research study change request
Agency / institution:
U.S. Food and Drug Administration (FDA)
Author:
Not specified
Target audience:
Researchers, participants in consumer studies
Effective period:
July 22, 2020
Approval date:
July 22, 2020
Date of changes:
July 22, 2020
Incentive amount:
$50
Incentive justification:
Compensation for time and participation in remote cognitive interviews
Technical requirements:
Computer and broadband Internet
Incentive comparison:
Below market rate, similar studies offer $100-$175
Year:
Not specified
Region / city:
Not specified
Topic:
Surgery, Tendon Treatment
Document type:
Medical guidelines
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Medical professionals
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Context:
Medical source detailing the indications for annular ligament desmotomy in the treatment of tendon issues.
Year:
2023
Region / City:
UK
Topic:
Geographical Indications
Document Type:
Decision
Organization / Institution:
Secretary of State
Author:
Secretary of State
Target Audience:
Interested parties and stakeholders
Period of validity:
From 24th July 2023
Approval Date:
24th July 2023
Date of changes:
N/A
Year:
2019
Region / City:
Gulfcoast Ultrasound Institute
Theme:
Ultrasound-Guided Regional Anesthesia
Document Type:
Course Itinerary
Organization / Institution:
Gulfcoast Ultrasound Institute
Author:
Michael Herrick, MD
Target Audience:
Physicians, Medical Professionals
Period of Validity:
N/A
Approval Date:
N/A
Date of Changes:
N/A